E0771-luc Orthotopic Mouse Model Service for Breast Cancer

The E0771-luc orthotopic mouse model offers a syngeneic, immunocompetent platform on the C57BL/6 background for studying hormone-responsive breast cancer progression and evaluating novel therapeutic strategies in a genetically tractable host. Alfa Cytology provides end-to-end E0771-luc orthotopic model services—from luciferase-engineered cell banking and surgical implantation through longitudinal BLI monitoring and multi-organ endpoint characterization—designed to accelerate your preclinical discovery pipeline with reproducible, audit-ready data.

Overview of E0771-luc Orthotopic Mouse Model for Breast Cancer

The E0771 (also designated EO771) mammary carcinoma cell line was originally isolated from a spontaneous tumor arising in a C57BL/6 mouse, making it one of the few breast cancer models native to the most widely used inbred mouse strain in biomedical research. Unlike xenograft systems that require immunodeficient recipients, E0771 grows as a syngeneic allograft in immunocompetent C57BL/6 mice, preserving full T-cell, B-cell, NK-cell, and myeloid compartment functionality throughout tumor evolution. Molecular characterization has revealed a luminal B–like phenotype: estrogen receptor α (ERα) negative, estrogen receptor β (ERβ) positive, progesterone receptor (PR) positive, and ErbB2 positive, with demonstrated sensitivity to anti-estrogen agents including tamoxifen, 4-hydroxy-tamoxifen, and fulvestrant. This endocrine responsiveness, combined with the model's compatibility with a vast array of genetically modified C57BL/6 strains—spanning knockout, knock-in, and transgenic lines—makes E0771 uniquely suited for dissecting tumor–immune interplay, metabolic co-morbidities, and hormone-directed therapies within a physiologically intact microenvironment.

Fig 1. E0771 GLSᶜᴷᴼ In situ model tumor volume (A), tumor weight (B), Ki67 IHC (C/D), cleaved caspase-3 (E/F), lung metastases H&E (H) and lung surface metastases (I). (Edwards, Deanna N., et al., 2021)

The luciferase-engineered derivative, E0771-luc, enables non-invasive, quantitative monitoring of primary tumor burden and micrometastatic dissemination via bioluminescence imaging (BLI) after systemic luciferin administration. When implanted orthotopically into the mammary fat pad, E0771-luc tumors exhibit high take rates approaching 100% and form palpable masses within 2–3 weeks, with spontaneous metastasis to lung and liver documented in the literature. The model has been extensively leveraged to evaluate cytotoxic chemotherapy, radiotherapy, anti-angiogenics, immune checkpoint inhibitors, dendritic cell–based vaccines, and phytonutrient interventions. Its relatively moderate metastatic pace compared to more aggressive lines affords a broader therapeutic window for assessing both primary tumor regression and distant organ seeding, while the C57BL/6 background ensures seamless integration with metabolic disease models, exercise intervention studies, and advanced immunophenotyping workflows.

Cell Line Information: E0771-luc

E0771-luc is a firefly luciferase–expressing derivative of the parental E0771 murine mammary adenocarcinoma cell line, enabling real-time, quantitative assessment of tumor burden and metastatic spread via in vivo bioluminescence imaging. The parental line was established from a spontaneous mammary tumor in a C57BL/6 mouse and has been extensively characterized at the transcriptomic and protein levels. The table below summarizes the essential characteristics of the E0771-luc cell line as applied in preclinical breast cancer research.

Our Services

Alfa Cytology maintains E0771-luc cells under stringent quality controls, including routine mycoplasma testing, short tandem repeat (STR) authentication, and in vitro luciferase activity validation before every in vivo campaign. Our surgical and imaging teams work in concert to deliver reproducible tumor kinetics, quantitative BLI datasets, and comprehensive histopathological endpoints—ensuring that each study generates robust, decision-ready preclinical evidence tailored to your therapeutic program.

Workflow of E0771-luc Orthotopic Mouse Model Construction

Building the E0771-luc orthotopic model requires coordinated execution across cell culture, surgical implantation, longitudinal imaging, and terminal analysis phases. The protocol outlined below balances standardization for reproducibility with flexibility to accommodate study-specific modifications such as combination therapy arms, primary tumor resection, or immune profiling timepoints. All animal procedures are performed under IACUC-approved protocols with continuous welfare monitoring.

1. Cell Expansion & Luciferase Validation: E0771-luc cells are thawed from authenticated, low-passage cryogenic stocks and expanded in antibiotic-containing medium to maintain reporter expression. Prior to in vivo use, cells are validated for luciferase signal intensity by incubating an aliquot with D-luciferin substrate and measuring photon output on a luminometer, ensuring adequate brightness for longitudinal BLI.
2. Cell Harvest & Preparation: On the day of surgery, confluent E0771-luc cells are detached with trypsin-EDTA, washed twice in ice-cold PBS, and counted via hemocytometer. Cell viability is confirmed by trypan blue exclusion. The cell suspension is prepared at a concentration of 1 × 10⁷ cells/ml in cold PBS, and an equal volume of chilled basement membrane matrix is added to achieve a final density of 5 × 10⁵ cells per 50 µl injection.
3. Animal Preparation & Anesthesia: Female C57BL/6 mice aged 5–8 weeks are group-housed and acclimatized for a minimum of 5–7 days. On the procedure day, mice are anesthetized with isoflurane (2–3% in medical oxygen) delivered via nose cone, and the lower right abdominal quadrant is shaved and sterilized with alternating povidone-iodine and 70% ethanol swabs.
4. Orthotopic Mammary Fat Pad Injection: A 50 µl suspension containing 4–5 × 10⁵ E0771-luc cells in basement membrane matrix is drawn into a ½ cc insulin syringe fitted with a 27 G needle. The needle is inserted into the 4th inguinal mammary fat pad at a shallow tangential angle to deposit the cell-matrix mixture within the glandular stroma. The injection site is held with forceps for 10 seconds post-injection to prevent reflux, and mice are recovered on a heated pad under observation.
5. Baseline & Longitudinal Bioluminescence Imaging: Beginning 7–10 days post-implantation, mice are imaged weekly via an in vivo imaging system. Each mouse receives an intraperitoneal injection of D-luciferin (150 mg/kg body weight), is anesthetized with isoflurane, and positioned for dorsal and ventral image acquisition. Regions of interest are drawn over the mammary gland and thoracic/abdominal cavities to quantify primary tumor photon flux and detect early metastatic seeding.
6. Tumor Monitoring & Volume Calculation: In parallel with BLI, tumor dimensions are measured every 2–3 days using digital calipers, and volume is calculated by the modified ellipsoid formula (length × width² × 0.5). Body weight and clinical signs are recorded at each measurement interval to ensure compliance with humane endpoint criteria.
7. Study Intervention & Optional Tumor Resection: When tumors reach protocol-specified size thresholds (commonly ~1,000 mm³ or ~30 days post-implantation), investigational compounds or vehicle controls are administered according to the study design. For metastasis-focused protocols, primary tumors may be surgically excised en bloc under anesthesia to extend survival and allow micrometastatic lesions to progress into macroscopic disease over an additional 3–4 weeks.
8. Terminal Endpoint & Multi-Organ Analysis: At study termination, mice are euthanized and subjected to ex vivo BLI of harvested organs (mammary gland, lungs, liver, spleen, lymph nodes, bone). Tissues are fixed in 10% neutral buffered formalin for paraffin embedding, sectioned for H&E staining, and subjected to immunohistochemistry (e.g., Ki67, CD31, F4/80) or flow cytometry for immune phenotyping, yielding a comprehensive preclinical dataset.

Fig 2. E0771-luc Orthotopic Mouse Model construction workflow.

Case Study-E0771-luc Orthotopic Mouse Model Development

In a recent preclinical program, Alfa Cytology deployed the E0771-luc orthotopic model to evaluate the efficacy of a novel immune checkpoint inhibitor in combination with an anti-estrogen agent. Following mammary fat pad implantation of E0771-luc cells, tumor-bearing C57BL/6 mice were randomized into vehicle control, monotherapy, and combination therapy cohorts once tumors reached approximately 200 mm³. Longitudinal BLI revealed differential growth kinetics across treatment arms, with the combination group showing marked suppression of primary tumor photon flux relative to either monotherapy alone. Flow cytometric analysis of tumor-infiltrating lymphocytes at the terminal endpoint demonstrated an increased CD8⁺ T-cell to regulatory T-cell ratio in the combination cohort, alongside reduced myeloid-derived suppressor cell accumulation in the spleen. Histopathological examination confirmed decreased Ki67 proliferation indices and diminished microvessel density within treated tumors, providing mechanistic support for the observed anti-tumor activity in this immunocompetent, hormone-responsive preclinical setting.

Why Choose Alfa Cytology?

Selecting Alfa Cytology as your partner for E0771-luc orthotopic studies means entrusting your preclinical program to a team that combines deep model expertise with integrated analytical capabilities and uncompromising quality standards. We treat every study as a bespoke scientific engagement, not a routine service transaction.

• Our E0771-luc master cell bank undergoes rigorous STR profiling, mycoplasma screening, and luciferase expression validation to guarantee genetic integrity and reporter fidelity across every campaign.
• In-house IVIS® or equivalent bioluminescence imaging systems enable quantitative, non-invasive tumor tracking with standardized region-of-interest analysis and automated photon flux reporting.
• The C57BL/6 background expertise within our vivarium allows seamless integration of genetically modified mouse strains, metabolic disease models, and specialized diet regimens into your study design.
• Surgical teams perform orthotopic mammary fat pad implantations with >95% tumor take rates, minimal perioperative mortality, and consistent tumor growth kinetics validated across multiple historical cohorts.
• Flexible dosing schedules accommodate single-agent, combination, and sequential therapy arms with pharmacokinetic sampling, biomarker collection, and interim necropsy options available on demand.
• Terminal analysis packages span digital histopathology, multiplex immunofluorescence, flow cytometry, and cytokine profiling—all processed within our centralized analytical laboratory to minimize inter-batch variability.
• Dedicated project scientists deliver weekly data summaries, interim statistical analyses, and protocol amendment support, ensuring transparent communication and agile response to emerging findings throughout the study duration.

Contact Us

If your preclinical program demands a robust, immunocompetent breast cancer model with built-in bioluminescence tracking on the versatile C57BL/6 background, Alfa Cytology's E0771-luc orthotopic service is engineered to deliver the evidence you need. Contact us today to discuss your study objectives, review our standard operating procedures, and receive a customized study proposal with timeline and pricing tailored to your specific therapeutic hypothesis and endpoint requirements.

For research use only. Not intended for any clinical use.